In Categories: Economic Impact

Results show exciting promise for reducing dependence on medications and alleviation of the massive cost burden for people living with type 2 diabetes.  

SAN FRANCISCO, California – June 5, 2019: Virta Health, the first company with a treatment to safely and sustainably reverse type 2 diabetes (T2D), today announced the publication of two-year peer-reviewed research from its ongoing clinical trial, now over three years in duration. Published in Frontiers in Endocrinology, the results demonstrate sustained diabetes reversal—reducing HbA1c below the diagnostic threshold for T2D while eliminating diabetes-specific medications—in 54% of two-year completing patients.

These outcomes represent a milestone in sustainability and continue to challenge the notion that T2D is a life-long sentence of disease progression and medication use. Among the 74% of patients enrolled in the Virta Treatment at two years, 67% of diabetes-specific prescriptions were discontinued, and patients simultaneously experienced a 0.9 improvement in HbA1c. Ninety-one percent of patients who began on insulin were able to reduce or eliminate their dosage. On average, patients lost and sustained the loss of 12% of their initial body weight at two years.

No significant changes were observed in the usual care group, which underscores the acute need to find new solutions for T2D now. The epidemic only continues to grow, with prediabetes and type 2 diabetes affecting more than a 100 million people in the U.S. alone. The total economic burden of T2D in the U.S has exceeded $400 billion annually, an average of $13,240 per diagnosed individual. Estimates of medication cost reductions for patients on insulin are nearly $5,000 annually.

“These results are exciting because they give millions of people living with Type 2 diabetes proof that they can reverse their type 2 diabetes, transform their health, and reduce dependency on expensive medications—and sustain the rapid positive results for years,” said Sami Inkinen, Virta Health co-founder and CEO. “We are getting patients off of drugs, like insulin, they thought they’d be on for the rest of their lives.”

Today’s publication also highlights the long-term positive impact of the Virta Treatment on T2D comorbidities, such as cardiovascular, liver, kidney, thyroid and inflammation-related markers. Notably, patients experienced an average 22% reduction in triglycerides and a 19% increase in HDL-C. Patients also showed a 78% reduction in non-alcoholic liver fibrosis score (NFS), which is a calculated biomarker related to non-alcoholic fatty liver disease (NAFLD), a $100B problem in the US today.

“Historically, the best medicine could do for type 2 diabetes was control it with lifestyle intervention and medications, “ said Robert Ratner, MD, Professor of Medicine at Georgetown University and former Chief Scientific and Medical Officer of the American Diabetes Association. “Virta is now providing us the first indication that long-term remission can be achieved, without the need or expense of drug therapy.”

Nina enrolled in the Virta Treatment three years ago. As she looked ahead to retirement, she realized she would eventually lose the insurance that covers most of her medication costs—in particular, the cost of the insulin she had been on for 20 years.

Within 8 months with Virta, she was off all of it, and her A1c is down to 6.4% from a starting point of 9.0%.

“I really do believe that I have gained 10 or 15 years on what I might have lived otherwise,” said Nina, a Virta Trial Patient in the third year of treatment. “After the first 2 years of Virta, I told my husband, ‘You know, I’m going to give you a run for your money. I’m going to live as long as you do.’ I truly believe that I’ve extended my lifespan by many, many years.”

For more information on the benefits of the Virta Treatment and to view the full paper, please visit

About Virta Health

Virta Health provides the first treatment to safely and sustainably reverse type 2 diabetes without medications or surgery. Among enrolled patients in our clinical trial at one year, 60% achieved diabetes reversal and 94% of insulin users reduced or eliminated usage altogether. Results extend beyond diabetes reversal to other areas of metabolic and cardiovascular health, with sustained improvements in blood pressure, inflammation, liver function, and BMI. For enterprises, Virta puts 100% of its fees at risk and can reduce medical prescription costs by more than 70% in year 1 alone. Delivered through Virta’s novel continuous remote care platform, the Virta Treatment provides unparalleled medical and behavioral support and is transforming the lives of people living with type 2 diabetes. To learn more, visit or follow us on Twitter @virtahealth.

Media Contact:

Paul Sytsma

Virta Health



  1. Avatar

    Congratulations and thank you for the great research. Now, let’s hope it’s embraced by all to improve the health of Americans!


  2. Avatar

    Amazing! Great work.


  3. Avatar
    Rakesh Kumar Gupta June 6, 2019 at 4:56 am

    Kindly keep the work doing. Best of Luck.


  4. Avatar

    Dr. Onyejekwe’s stats seem different. He says 19% of trial population saw partial or complete remission at 2 years and Sami Inkinen say’s 55% or the 74% still on the program at 2 years achieved T2D reversal. Can both be correct?
    The study as published in Frontier in Endocrinology in it’s introduction says 11.5 at 1 year and 9.2% at 2 years achieved partial and complete remission.
    Please clarify.


    1. Virta Health

      Thank you for your patience while waiting for a response! The difference in percentages you are referring to is related to the difference in definitions between reversal and remission. Reversal is defined as achieving HbA1c below 6.5% while removing all diabetes-specific medications. It allows for the continuation of metformin. From the manuscript, “…prescriptions for metformin were usually continued given its role in preventing disease progression (10, 59), preserving β-cell function (59) and in the treatment of pre-diabetes per guidelines (28).” Remission implies glycemic control without any medication use. We bring all of this to light in the paper. Supplementary tables 4 and 5 contain helpful data, too, that clarify the various disease outcomes.


  5. Avatar

    Correction: it was meant to read 55% of the 74% still in the program in my first post.


  6. Avatar
    Pradeep Awasthi June 6, 2019 at 3:15 pm

    This is a sequential epic of Virta’s success in achieving a care of excellence in type II diabetes by the novel approaches formulated by World’s renowned scientists and diabetes experts.Its certainly an incredible mode of getting remission from expensive treatment by becoming a part of Virta treatment protocol.


  7. Avatar
    Pierre D Curtis June 7, 2019 at 12:55 am

    Wonderful news. Congratulations on this milestone. I adopted the LCHF lifestyle on 5th Nov 2019. So far I have lost 73 lbs and my A1c went from 8.5% to 6.0% Off my BP meds and oral meds for diabetes, my insulin dose went from a massive 240 units a day to 27 units a day. I had to insist that my endocrinologist give me a prescription for a CAC scan, my Insurance wouldn’t pay for the scan so I paid for the scan, $150. Results came back Calcium Score very high at 2200, not good I know, but I’m so glad I know that and can take the needed actions. Now I’m taking a low dose statin to see if I can slow or reverse the plaque along with the LCHF IF Keto lifestyle. BTW: My doctor of 20yrs had become indifferent to my treatment, suddenly got a big surprise when he got my Calcium score. Wanted me to go back to high carb low fat and prescribe me a large dose statins again along with other meds that have failed me over twenty years. During my visit he didn’t even notice my 70 lb weight loss or that my A1c was 6.0% and I had to force him to give me the prescription for the CAC scan. Pierre Curtis


Leave a reply

Your email address will not be published.